Stock Events

Stock Events

Brii Biosciences Limited 

$0.130000
0
+$0.00+0%Friday 20:00

Statistics

Day High
0.2459
Day Low
0.2312
52W High
0.2459
52W Low
0.12575
Volume
4,154
Avg. Volume
113
Mkt Cap
95.5M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Aug 20Expected
Q4 2023
Q2 2024
Q4 2024
Q2 2025
Q4 2025
Q2 2026
-0.15
-0.1
-0.05
0
Expected EPS
N/A
Actual EPS
-0.0206052

Financials

-1,177.97%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
2.66MRevenue
-31.33MNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap211.7B
Gilead Sciences is a major player in the development of antiviral drugs, directly competing with Brii Biosciences in the infectious disease market.
Vertex Pharmaceuticals
VRTX
Mkt Cap141.65B
Vertex Pharmaceuticals focuses on serious diseases, including viral infections, which overlaps with Brii Biosciences' focus areas.
Regeneron Pharmaceuticals
REGN
Mkt Cap95.99B
Regeneron Pharmaceuticals competes in the biopharmaceutical field targeting infectious diseases, similar to Brii Biosciences.
Moderna
MRNA
Mkt Cap88.52B
Moderna is known for its mRNA technology used in vaccines, competing in the infectious disease space where Brii Biosciences is also active.
BioNTech
BNTX
Mkt Cap22.15B
BioNTech competes with Brii Biosciences in the development of treatments and vaccines for infectious diseases.
Arbutus Biopharma
ABUS
Mkt Cap834.03M
Arbutus Biopharma is involved in antiviral drug development, making it a direct competitor in Brii Biosciences' core market.
Inovio Pharmaceuticals
INO
Mkt Cap62.29M
Inovio Pharmaceuticals focuses on DNA medicines including vaccines for infectious diseases, aligning as a competitor to Brii Biosciences.
Novavax
NVAX
Mkt Cap1.66B
Novavax is involved in the development of vaccines for infectious diseases, directly competing with Brii Biosciences.

About

Founded in Beijing, China, in 2017, Brii Biosciences Limited is a biopharmaceutical firm dedicated to discovering and developing innovative therapies for infectious diseases and central nervous system disorders. Its diverse pipeline features: early-stage (Phase 1) compounds BRII-778 and BRII-732 for treating HIV; a multifaceted approach to Hepatitis B (HBV) including a Phase 2 combination study of BRII-179 and BRII-835, with BRII-179 (a recombinant protein-based immunotherapeutic) also in Phase 1b/2a, and BRII-835 having successfully completed Phase 2 for chronic HBV patients. The company also offers the Amubarvimab/romlusevimab combination as a treatment for COVID-19. Beyond these, Brii Biosciences is advancing BRII-296 for PPD and BRII-297 for various depressive conditions, alongside several agents targeting highly resistant infections: BRII-636, BRII-672, and BRII-693 are designed to combat multi-drug and extensively drug-resistant (MDR/XDR) gram-negative bacteria, while BRII-658 is under development for MDR/XDR tuberculosis and non-tuberculosis mycobacterial infections.
Show More
CEO
Zhi Hong
Employees
80
Country
China
ISIN
KYG1645A1094
WKN
000A3CTND

Listings

STU
DE
7SS.STU
HK
HK
2137.HK
MU
DE
7SS.MU
OTC Link
US
BRIBF

0 Comments

Share your thoughts

FAQs

What is Brii Biosciences Limited stock price today?▼
The current price of BRIBF is $0.13 USD — it has increased by +0% in the past 24 hours. Watch Brii Biosciences Limited stock price performance more closely on the chart.
What is Brii Biosciences Limited stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Brii Biosciences Limited stocks are traded under the ticker BRIBF.
Is Brii Biosciences Limited stock price growing?▼
BRIBF stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Brii Biosciences Limited has showed a -45.97% decrease.
What is Brii Biosciences Limited market cap?▼
Today Brii Biosciences Limited has the market capitalization of 95.5M
When is the next Brii Biosciences Limited earnings date?▼
Brii Biosciences Limited is going to release the next earnings report on March 19, 2027.
What were Brii Biosciences Limited earnings last quarter?▼
BRIBF earnings for the last quarter are -0.02 USD per share, whereas the estimation was N/A USD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Brii Biosciences Limited revenue for the last year?▼
Brii Biosciences Limited revenue for the last year amounts to 2.66M USD.
What is Brii Biosciences Limited net income for the last year?▼
BRIBF net income for the last year is -31.33M USD.
How many employees does Brii Biosciences Limited have?▼
As of November 7, 2026, the company has 80 employees.
In which sector is Brii Biosciences Limited located?▼
Brii Biosciences Limited operates in the Health & Wellness sector.
When did Brii Biosciences Limited complete a stock split?▼
Brii Biosciences Limited has not had any recent stock splits.
Where is Brii Biosciences Limited headquartered?▼
Brii Biosciences Limited is headquartered in Beijing, China.